Introduction
============

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease. Patients gradually lose the ability to control their muscles and 3--5 years following diagnosis, they typically experience respiratory failure and succumb ([@b1-etm-0-0-5868]). Patient\'s ALS Assessment Questionnaire (ALSAQ-40) scores decrease from 40 (normal motor capabilities) at the onset of disease to 0 (total loss of motor capabilities) over an average of 4.4 years ([@b1-etm-0-0-5868],[@b2-etm-0-0-5868]). At present, no treatments are able to prevent ALS progression. Riluzole is the only drug that is currently approved for the treatment of ALS and typically increases life expectancy by 3--6 months ([@b3-etm-0-0-5868]--[@b7-etm-0-0-5868]). Vitamin E is also often prescribed to patients with ALS due to its anti-oxidizing activity ([@b8-etm-0-0-5868]). Potential novel treatments for ALS, including gabapentine, copaxone, topiramate, creatine and the use of progenitor cells, have been assessed; however, no beneficial effects have been observed ([@b9-etm-0-0-5868]). Therefore, novel, effective treatments for ALS are required.

Endotherapia is a novel therapeutic strategy that has been used to treat chronic conditions, including autoimmune, neurodegenerative and proliferative diseases ([@b10-etm-0-0-5868]--[@b12-etm-0-0-5868]). This therapy uses small molecules, including vitamins, amino acids and fatty acids, linked to poly-L-lysine (PLL) ([@b10-etm-0-0-5868]--[@b12-etm-0-0-5868]). PLL linkage increases the availability of vitamins, amino acids and fatty acids *in vivo* ([@b10-etm-0-0-5868]--[@b12-etm-0-0-5868]). Two drug candidates, multiple sclerosis (MS)-Endotherapia (GEMSP) and ALS-Endotherapia (GEMALS), have been assessed in patients with MS and ALS, respectively ([@b13-etm-0-0-5868]--[@b16-etm-0-0-5868]). The beneficial effects of GEMALS on ALS have previously been demonstrated in a superoxide dismutase 1 (SOD1) rat model of ALS ([@b12-etm-0-0-5868]) and in a small clinical trial (n=12) ([@b11-etm-0-0-5868]). In the rat model, GEMALS delayed the onset of disease and increased the rat\'s lifespan ([@b12-etm-0-0-5868]). In humans the results obtained were promising; 83% of patients exhibited stabilization or improvement to their functional capacities ([@b11-etm-0-0-5868]). Furthermore, treatment with GEMALS reversed the functional capacity impairment (50.07%) and increased patient life expectancy by 52.57 months ([@b11-etm-0-0-5868]).

The aim of the present study was to confirm the beneficial action of GEMALS in a larger sample of patients with ALS (n=31) and to further investigate the effect of GEMALS on specific motor parameters that were not assessed in the previous study ([@b11-etm-0-0-5868]).

Patients and methods
====================

### Patients

A total of 31 patients (10 women, 35.5%; 21 men, 64.5%) with ALS in the evolutive phase were enrolled in the present study (age range, 38--82 years). The patients were recruited from January 1994 to December 2011 ([Table I](#tI-etm-0-0-5868){ref-type="table"}). There were no exclusion criteria. ALS diagnosis was performed by a neurologist at the French University hospitals located in Nantes, Marseille, Nîmes, Versailles, Dijon, Henry-Mondor de Créteil, Nice, Grenoble, Paris, Lille, Poitiers, Toulouse, St Etienne, Rennes, Metz, Montpellier and Angers using standardised clinical criteria and electromyogram tests as previously described ([@b17-etm-0-0-5868]). The study was national, multicenter, non-randomized and non-blinded. The duration of GEMALS treatment was between 3 and 140 months ([Table I](#tI-etm-0-0-5868){ref-type="table"}) and patients were evaluated 3 or 4 times per year. The following data were collected for each patient: Age, sex and date of diagnosis, start/finish of GEMALS treatment and ALS Assessment Questionnaire (ALSAQ-40) scores over time ([Table I](#tI-etm-0-0-5868){ref-type="table"}). All patients provided prior informed written consent for inclusion in the current study.

### GEMALS synthesis and dose

A dose of (60--180 µg/kg/day) GEMALS was administered via the sublingual route. Initially all patients were administered 60 µg/kg/day, however the dosage was doubled (when there was a loss of 1 point of the ALSQ-40 score in 1 month) or tripled (when doubled dose was not enough to reduce the deterioration and there was a decrease of ≥1 point of the ALSQ-40 score in 1 month) if the patients condition deteriorated. As previously described, GEMALS was synthesized according to patent numbers 792167 (EU) and 6114388 (USA) ([@b12-etm-0-0-5868]) and purchased from Farmacia Legnani (Milan, Italy). GEMALS contains a mixture of functional polypeptides: Fatty acids (including thioctic acid and oleic acid), antioxidants (including ascorbic acid), free radical scavengers and amino acids (including taurine and methionine), all linked to PLL ([Table II](#tII-etm-0-0-5868){ref-type="table"}). If patients presented with an acceleration of the disease during follow up, the dosage of GEMALS was doubled to maintain its protective effect.

### Score

ALS evaluation was based on the evolution of ALSAQ-40 scores throughout the follow-up period, with scores ranging from 40 (normal) to 0 (total loss of motor capabilities). Two ALSAQ-40 scores were defined and compared: M score, which was the score of each patient in the present study determined during follow-up visits; R score, which was the worldwide reference score of theoretical disease progression without treatment (mean ALSAQ-40 score decrease is 0.769 points/month). Each score was measured as previously described ([@b18-etm-0-0-5868],[@b19-etm-0-0-5868]). ALSAQ-40 is a patient health status report used to measure the subjective well being of ALS patients and is primarily used in clinical trials for novel ALS drugs ([@b20-etm-0-0-5868],[@b21-etm-0-0-5868]). ALSAQ-40 is sensitive, reliable and an acceptable tool for the assessment of quality of life in patients with ALS ([@b2-etm-0-0-5868],[@b20-etm-0-0-5868]). To estimate the effect of GEMALS treatment, a reference curve of the mean individual evolution of ALSAQ-40 score over time was constructed. Patient responses were evaluated as follows: Progression, the individual mean speed of evolution of ALSAQ-40 score with GEMALS was ≤R score (−0.769 points/month); decrease, the individual mean speed of evolution of ALSAQ-40 score with GEMALS was between −0.769 and 0 points/month; stabilization, the individual mean speed of evolution of ALSAQ-40 score with GEMALS was 0 points/month; and improvement, the individual mean speed of evolution of ALSAQ-40 score with GEMALS was \>0 points/month.

### Statistical analysis

Due to the high variability of the ALS cohort included in the present study, a previously published method of adapted valuation was used ([@b11-etm-0-0-5868]). The Mann-Whitney U test was used to compare the study population with the reference population. Analyses were performed using SAS Version 9 (SAS Institute, Inc., Cary, NC, USA) and statistical analysis was conducted externally by Stalphamis (Le Bourg, France). P\<0.05 was considered to indicate a statistically significant difference.

A comprehensive study of the ALSAQ-40 score, ALSAQ-40 evolution and the evolution of the ALSAQ-40 score based on each item was performed. For descriptive analysis, the following parameters were investigated: Strength, percentage, distribution, minimum, 1st quartile, median, 3^rd^ quartile, maximum, mean, standard deviation and 95% confidence intervals. For comparative analysis, Student\'s t test was used to compare final M and R scores. The equality of variance was verified using the folded F test. Evolution of the ALSAQ-40 score was analyzed using a linear regression model and the following parameters were used to analyze M and R scores: Coefficient of correlation (R^2^) and associated P-value, intercept and slope (ax+b). A χ^2^ or Fisher\'s exact test were used to compare success and failure rates according to the theoretical strength obtained by unilateral assumption (% success \>% of failure).

Results
=======

### General considerations

In the 31 patients treated with GEMALS, 16.13% experienced a worsening of their condition (degradation), 70.97% experienced a decrease in the progression of the disease (deceleration) and 12.90% experienced a reversal of disease evolution (improvement) ([Fig. 1](#f1-etm-0-0-5868){ref-type="fig"} and [Table III](#tIII-etm-0-0-5868){ref-type="table"}). When the final score was higher than the initial score, the disease was considered to have improved. When the initial and final scores were equal or the final M score was higher than the R score, the disease was considered to have decelerated. When the final M score was lower than the R score, the evolution was considered have degraded ([Fig. 1](#f1-etm-0-0-5868){ref-type="fig"} and [Table III](#tIII-etm-0-0-5868){ref-type="table"}). The mean duration of GEMALS treatment was of 988 days with a standard deviation of 902 days (minimum, 98 days; maximum, 4,287 days). The mean score evolution of patients treated with GEMALS was −0.40 points/month and the worldwide reference score evolution was −0.77 points/month ([Fig. 2](#f2-etm-0-0-5868){ref-type="fig"}); this represents a significant increase in life expectancy of 38 months (3.16 years). A total of 83.87% of patients treated with GEMALS had an improvement in the evolution of ALS following GEMALS treatment (P\<0.0001; [Table III](#tIII-etm-0-0-5868){ref-type="table"}). Additionally, no side effects were reported and following rigorous questioning of the patient no clinical symptoms including, cutaneous alterations, flu-like symptoms, gastrointestinal troubles, migraines, cephalea, insomnia, nauseas and vomiting were described. Additionally the biological parameters (blood cell count, ionograms, lipidic balance, hepatic enzymes, renal filtration or glycaemia) were unaltered.

### Item scores

Following GEMALS treatment, the M score was significantly higher than the R score for the following functions: Speech (P\<0.005), salivation (P\<0.001), swallowing (P\<0.001), writing (P\<0.05), ability to turn in bed (P\<0.05), walking (P\<0.01) and breathing (P\<0.001) ([Table IV](#tIV-etm-0-0-5868){ref-type="table"}). No significant differences between M and R scores were observed for ability to cut food, ability to dress and ability to climb stairs ([Table IV](#tIV-etm-0-0-5868){ref-type="table"}).

### Item score evolutions

Patients were considered to have improved if there was an increase in the M score over time. If the M score decreased over time and this decrease was \<0.769 points/month, patients were considered to have decelerated. Patients were considered to have degraded if the M score decreased throughout the treatment period at \>0.769 points/month. Improvement and deceleration indicate treatment success and degradation indicates treatment failure. Items with a success rate \>50% are presented in [Fig. 3](#f3-etm-0-0-5868){ref-type="fig"}. The results indicate that the success rate for breathing was significantly greater than the failure rate (P\<0.05; [Fig. 3](#f3-etm-0-0-5868){ref-type="fig"}).

### Overall study

Overall evolutions for each patient were calculated by linear regression, the evolution category (improvement, deceleration and degradation) mean values are presented in [Table V](#tV-etm-0-0-5868){ref-type="table"}. The mean overall M score was 19.8, which was significantly higher than the mean overall R score of 11.7 (P=0.0013). The mean values at the end of the study represent an amelioration of the M group vs. the R group at 30.8% (P=0.0002). The study population included 10 women and 21 men; the success rate of treatment was 100% for women and 76.19% for men ([Table III](#tIII-etm-0-0-5868){ref-type="table"}; P\<0.0001). Overall the treatment was significantly successful (P\<0.0001; [Table III](#tIII-etm-0-0-5868){ref-type="table"} and [Fig. 4](#f4-etm-0-0-5868){ref-type="fig"}).

Discussion
==========

In a previous study using a SOD1 rat model, it was demonstrated that GEMALS significantly extended lifespans and improved electromyographic parameters ([@b12-etm-0-0-5868]). However, no significant increase in life expectancy was observed when rats were treated with Riluzole or other pharmacological agents, including minocycline and nifedipine ([@b12-etm-0-0-5868]). Two GEMALS concentrations were also assessed and the results suggested that the effects of GEMALS may be dose-dependent ([@b12-etm-0-0-5868]). Based on these results, the higher dose (3.75 mg/ml) administered to SOD1 rats was extrapolated for use in the present study in humans (4--12.05 mg/day). In the SOD1 animal model and humans GEMALS demonstrated a beneficial effect.

The effect of GEMALS in 12 patients with ALS has been previously reported ([@b11-etm-0-0-5868]). The results indicated that GEMALS treatment caused a 50.07% decrease in the loss of functional capacities, corresponding to a mean life expectancy increase of 52.57 months (4.38 years). In the present study, there was an increase in life expectancy of 38 months (3.16 years). Each study indicates that GEMALS is an effective method of treating ALS, with beneficial effects observed in 83% of patients in the previous report ([@b11-etm-0-0-5868]) and 83.7% in the present study. In the previous study ([@b11-etm-0-0-5868]), the ALSAQ40 was reported; however, data regarding specific functions, including speech, were not available. In the present study, the effect of GEMALS treatment on specific functions was evaluated and significant improvements in breathing, walking, salivation, speech, swallowing and writing were observed.

The glutamate release blocker Riluzole is, at present, the only authorized treatment for ALS; however, Riluzole treatment extends life expectancy by only a few months ([@b3-etm-0-0-5868]). It has been demonstrated that treatment with Riluzole for 12 months reduces deterioration of muscular function by 33.4% and extends life expectancy by 2.77 months ([@b4-etm-0-0-5868]). It has also been reported that treatment with Riluzole for 12 months extends survival by 4.2 months; however, this advantageous effect is transient and disappears when the monitoring period is extended ([@b5-etm-0-0-5868]). This transient effect has been reported in another study, with Riluzole only effective at treating patients affected by the bulbar form of ALS, which represents \~30% of all ALS cases ([@b18-etm-0-0-5868]).

It has previously been reported that GEMALS treatment decreases the loss of functional capacities that occurs in patients with ALS ([@b11-etm-0-0-5868]). No side effects have been reported following treatment with GEMALS or GEMSP ([@b13-etm-0-0-5868]). Similarly, in the current study, no side effects following GEMALS treatment were reported. This may be due to the low dose of GEMALS received by each patient. The individual doses administered were calculated according to the evolution of each patient at follow-up; thus, doses ranged from 60 to 180 µg/kg/day. PLL accounts for \~90% of the drug molecular weight, therefore only 0.4--1.2 mg of small molecules were delivered per administration.

To overcome the high variability of the ALS cohort studied here, the Mann-Whitney U test was used as previously reported ([@b11-etm-0-0-5868]). A total of 21 men and 10 women were included in the present study and the treatment success rates were 76.2 and 100%, respectively, however future studies should use a larger population size to confirm the results of the present study. Compared with Riluzole therapy, GEMALS increased the life expectancy of patients with ALS from 4 to 38 months ([@b3-etm-0-0-5868]). Compared with the GEMALS pilot study ([@b11-etm-0-0-5868]), the life expectancy of patients decreased from 52.57 to 38 months. However, if patients 26 and 27, who did not respond to treatment with GEMALS, were excluded from further analyses, the mean increase in life expectancy in the current study was 89 months (n=29).

The activity of Riluzole is based on the blockage of excitatory amino acid pathways. It blocks sodium dependent voltage channels, thus decreasing the release of glutamate ([@b22-etm-0-0-5868]). Taurine, one of the constituents of GEMALS, also reduces glutamate excitotoxicity by enhancing mitochondrial function and regulating intracellular calcium homeostasis ([@b23-etm-0-0-5868]). ALS is a multifactorial disease in which oxidative stress, mitochondrial damage, neuroinflammation, zinc excitotoxicity and apoptosis serve important roles. Treatment of ALS therefore requires a multifactorial strategy; GEMALS, a tailor-made combination therapy composed of functional polypeptides, was developed for this purpose. In the present study, the constituents of GEMALS were rigorously selected according to their known effects on the regeneration or protection of neuronal components ([@b10-etm-0-0-5868],[@b11-etm-0-0-5868]). These constituents were selected with the aim of decreasing oxidative and free radical stress, reducing inflammation, inhibiting exogenous toxic factors and exhibiting neuroprotective effects ([@b12-etm-0-0-5868]).

All PLL-linked molecules used in the present study are endogenous and non-immunogenic, allowing for long-term administration without the induction of toxicity and/or side effects. The quantities of PLL-linked molecules represent a low proportion (w/w) of the overall dosage, which may account for the absence of side effects following treatment with GEMALS and GEMSP ([@b11-etm-0-0-5868]). Free components not linked to PLL have been reported to have no therapeutic effect in experimental animal models ([@b14-etm-0-0-5868]--[@b16-etm-0-0-5868],[@b24-etm-0-0-5868]). PLL therefore appears to be more than a simple vector; PLL compounds exhibit therapeutic properties. PLL-linked molecules are able to cross the blood brain barrier, which is important as certain molecules, including butyrilcholinesterase (molecular weight, 340 KDa), are unable to do so alone ([@b25-etm-0-0-5868]). Furthermore, PLL-linkage may increase the active duration of molecules; for example, PLL-linked butyrilcholinesterase remains active for ≥72 h ([@b25-etm-0-0-5868]). The results of a previous study investigating GEMSP indicated that methionine-PLL, a constituent of GEMSP, was present in the motor neurons of the spinal cord ([@b15-etm-0-0-5868]), exerting potential neuroprotective action. This observation is similar to that of a different study, in which PLL was identified inside organelles and the nuclear membrane ([@b26-etm-0-0-5868]).

The constituents of GEMALS exert the following actions: i) Poly-unsaturated fatty acids exert a neuroprotective effect and act as free radical scavengers to prevent oxidation of unsaturated fatty acids in the cell membrane ([@b27-etm-0-0-5868],[@b28-etm-0-0-5868]); ii) α-tocopherol exerts a neuroprotective effect by potentially attenuating the entry of Ca^2+^ via transient receptor potential-like channels ([@b29-etm-0-0-5868]); iii) ascorbic acid is necessary for the maintenance of neuronal functions and exerts an antioxidant effect ([@b30-etm-0-0-5868]); iv) polyamine agmatine exerts a neuroprotective effect against the excitotoxic action of glutamate ([@b31-etm-0-0-5868]); v) cysteine, methionine, glutathione, retinoic acid, pantothenic acid and biotin act as antioxidants and scavengers to reduce the apoptosis and neuronal death induced by reactive oxygen species ([@b32-etm-0-0-5868]); and vi) taurine modulates mitochondrial calcium homeostasis ([@b33-etm-0-0-5868]).

In conclusion, a multifactorial strategy for the treatment of ALS is required and GEMALS may be an effective treatment. The present study is an in-depth investigation demonstrating and confirming the effectiveness of GEMALS in a larger cohort of patients with ALS. The results suggest that GEMALS treatment significantly increases life expectancy and decreases the loss of important motor functions in patients with ALS; however, a phase IIb multicentric, randomized and double-blinded clinical trial is required to confirm these results.
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###### 

Data for patients with amyotrophic lateral sclerosis in the present study.

            Diagnosis   GEMALS start   GEMALS end                    
  --------- ----------- -------------- ------------ ---- ------ ---- -----
    1 (M)   11/09       62               35.5       62   15     66   36
    2 (M)   01/08       60             31           63   13     65   28
    3 (M)   03/10       53             37           53   14.5   56   32
    4 (F)   --          --             17           64   15     64   7
    5 (F)   05/10       72             33           73   16     75   27
    6 (F)   01/09       59             12           60   12     62   19
    7 (M)   2007        65             27           69   23     71   23
    8 (F)   10/08       68             16           71   6      73   19
    9 (M)   09/10       36             28           38   20     39   9
  10 (M)    01/94       47             12           62   11     66   48
  11 (M)    01/04       53             33           60   35.5   63   36
  12 (M)    08/03       40             40           40   6.5    49   110
  13 (M)    01/94       47             12           62   11     66   48
  14 (M)    01/01       57             40           57   6      69   140
  15 (M)    --          --             35           74   27     76   15
  16 (F)    --          --               27.5       80   24     82   15
  17 (M)    03/08       44             31           46   17     49   24
  18 (F)    01/09       55             34           57   22     59   19
  19 (F)    --          --             37           63   32     64   11
  20 (M)    06/07       65             33           69   25     71   32
  21 (M)    07/07       61             34           65   18     67   26
  22 (F)    --          --             38           59   34.5   60   13
  23 (M)    02/08       73             37           74   25     76   21
  24 (M)    08/05       58             32           61   28     63   25
  25 (F)    11/08       44             35           47   36     49   28
  26 (M)    04/10       62             26           64   12     64   9
  27 (M)    12/11       68             27           70   23     70   3
  28 (M)    03/11       58             34           59   34     60   8
  29 (M)    07/07       57             29           59   17     63   50
  30 (F)    03/07       32             39           33   0      38   66
  31 (M)    01/01       46             20           53   28     58   57

M, male; F, female; GEMALS, amyotrophic lateral sclerosis-Endotherapia.

###### 

Amyotrophic lateral sclerosis-Endotherapia constituents.

  PLL constituents                             Final concentration (M)
  -------------------------------------------- -------------------------
  Glucosamine-PLL                              1×10^−04^
  Agmatine-PLL                                 1×10^−04^
  Uric acid-PLL                                1×10^−04^
  α-Tocopherol-PLL                             3×10^−05^
  Ascorbic acid-PLL                            3×10^−05^
  CoEnzyme Q10-PLL-oleic acid                  3×10^−05^
  Retinoic acid-PLL-oleic acid                 3×10^−05^
  Pantothenic acid-PLL                         3×10^−05^
  Biotin-PLL                                   3×10^−05^
  Oleic acid-PLL-thioctic acid                 1×10^−04^
  Oleic acid-PLL-myristic acid                 1×10^−04^
  Oleic acid-PLL-lauric acid                   1×10^−04^
  Oleic acid-PLL-linoleic acid                 1×10^−04^
  Oleic acid-PLL-palmitic acid                 1×10^−04^
  Oleic acid-PLL-palmitoleic acid              1×10^−04^
  Lauric acid-PLL-caprylic acid                1×10^−04^
  T-T-Farnesyl-L. cysteine-PLL-palmitic acid   1×10^−04^
  Cholesterol-PLL-oleic acid                   1×10^−04^
  L. Cysteine-PLL                              2×10^−04^
  Taurine-PLL                                  2×10^−04^
  L. Methionine-PLL                            2×10^−04^
  L. Glutathione-PLL                           1×10^−04^

PLL, poly-L-lysine.

###### 

Effects of amyotrophic lateral sclerosis-Endotherapia treatment (n=31).

                 No. patients (%)                                            
  -------------- ------------------ ----------- ------------ --------------- ----------
  Improvement    2 (9.52)           2 (20.00)   4 (12.90)    26/31 (83.87)   \<0.0001
  Deceleration   14 (66.67)         8 (80.00)   22 (70.97)                   
  Degradation    5 (23.80)          0 (0)       5 (16.13)                    

Success rate=(improvement + deceleration)/total. The P-value presented in this table is for success rate vs. degradation.

###### 

Scores according to each item.

  Item                      Inclusion   M                                                       R
  ------------------------- ----------- ------------------------------------------------------- ---------
  Speech                    2.9±1.4     2.3±1.7^[c](#tfn7-etm-0-0-5868){ref-type="table-fn"}^   1.2±1.1
  Salivation                3.3±0.9     2.6±1.4^[d](#tfn8-etm-0-0-5868){ref-type="table-fn"}^   1.3±1.1
  Swallowing                3.4±0.9     2.8±1.3^[d](#tfn8-etm-0-0-5868){ref-type="table-fn"}^   1.4±1.1
  Writing                   2.9±1.0     1.8±1.6^[a](#tfn5-etm-0-0-5868){ref-type="table-fn"}^   1.1±1.1
  Ability to cut food       2.6±1.3     1.5±1.3                                                 0.9±1.0
  Ability to dress          2.6±1.2     1.3±1.2                                                 1.0±1.1
  Ability to turn in bed    3.0±1.3     2.0±1.5^[a](#tfn5-etm-0-0-5868){ref-type="table-fn"}^   1.2±1.2
  Walking                   2.6±0.9     1.7±1.1^[b](#tfn6-etm-0-0-5868){ref-type="table-fn"}^   1.0±1.0
  Ability to climb stairs   2.2±1.3     1.1±1.2                                                 0.9±1.0
  Breathing                 3.1±1.2     2.7±1.4^[d](#tfn8-etm-0-0-5868){ref-type="table-fn"}^   1.3±1.2

Data are presented as the mean ± standard deviation.

P\<0.05

P\<0.01

P\<0.005

P\<0.001 vs. R. The inclusion values indicate the mean M score ± standard deviation of patients at the beginning of the study.

###### 

Global evolution mean values.

                       Mean values                                           
  -------------- ----- ------------- --------- ---------- ------- ---------- ----------
  Improvement      4   0.58          0.125     0.00234    −0.98   \<0.0004   −0.02075
  Deceleration   22    −0.86         \<0.049   −0.01357   −0.98   \<0.0003   −0.02325
  Degradation      5   −0.93         \<0.040   −0.03118   −0.94   \<0.0001   −0.02120
